Ssilverchair, page-3

Thanks for the support Analyst007 and everyone, I don't intend to go away, I intend to keep following CUV and showing comparisons, facts and figures for years more. Vitiligo is very close and a buyback is barely underway so there is no reason I would sell now as I don't see many better risk/reward opportunities than right here with Clinuvel at this undervaluation created by the Shorters. Steven didn't read my post properly I was actually comparing CUV to a rare profit making Biotech today in PME, here it is again:

Pro Medicus FY2023 Revenue $125 Million, Profit after tax $60.6Million. Market cap $11.8 Billion. P/E 194
Clinuvel, FY2023 Revenue $78 Million, Profit after tax $30.6Million . Market cap $0.77 Billion. P/E 25

Pro Medicus certainly has some very happy shareholders because that extra $11.0 Billion in market cap for just $30 Million more profit than CUV is really something to admire. What will CUV be worth with Vitiligo approval and even hitting just 50% of what they have forecast for years 1 and 2 and with 1.5 Million shares removed via the buyback? EPS will go through the roof. The only analyst who has priced it in has come up with a PT near $50, I expect others will price it in as results come to hand.

All IMO DYOR